GLP-1 for PCOS: what Ozempic, Wegovy, Mounjaro and Zepbound can and can't do

Can GLP-1 medicines treat PCOS?

Polycystic ovary syndrome affects roughly 10% to 13% of women of reproductive age, according to the 2023 international guideline. In 2026 an international consensus began renaming it polyendocrine metabolic ovarian syndrome (PMOS). The diagnostic criteria didn’t change: two of irregular cycles or ovulation problems, high androgens, and polycystic-looking ovaries or a high AMH level.

Because insulin resistance and higher weight are common in PCOS, many people ask whether semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) can help. The short answer: they can help with weight, but none of them is approved to treat PCOS itself. The US labels list type 2 diabetes for Ozempic and Mounjaro, and long-term weight management (plus other conditions) for Wegovy and Zepbound. If you meet those criteria, your doctor may prescribe one for that reason. Using them for PCOS symptoms alone is off-label.

What does the 2023 PCOS guideline say about GLP-1?

The guideline gives GLP-1 medicines a cautious, conditional place:

• For weight: anti-obesity medicines, naming liraglutide and semaglutide, could be considered in addition to active lifestyle changes for higher weight in adults with PCOS, following general obesity guidelines.
• Contraception: clinicians should make sure effective contraception is in place when pregnancy is possible, because pregnancy safety data are lacking.
• Slow start: doses should go up gradually to limit stomach side effects.
• Long-term view: shared decisions should cover side effects, the possible need for long-term use, the high risk of regain after stopping, and the lack of long-term safety data.
• Fertility: anti-obesity medicines for reproductive outcomes are recommended only in research settings for now.

Tirzepatide isn’t named, because the evidence review behind the guideline only searched studies up to July 2022. The guideline also stresses that a healthy lifestyle helps even without weight loss.

What do studies show for weight, periods and testosterone?

The trials are small and short, so treat the numbers below as early evidence rather than a promise.

Weight

• Liraglutide 3 mg (placebo-controlled, 32 weeks, 82 women): body weight fell 5.7% versus 1.4% with placebo. Stomach side effects affected 58% versus 19%.
• Semaglutide 1 mg plus metformin (open-label, 16 weeks, 100 women): about 6.1 kg lost versus 2.3 kg on metformin alone.
• Tirzepatide 5 mg plus metformin (open-label, 16 weeks, 60 women): about 10.4 kg versus 1.7 kg on metformin alone.
• A 2024 meta-analysis of four placebo-controlled trials found lower BMI (about 2.4 points) and a smaller waist (about 5 cm).

These studies used different doses and designs, so they can’t be compared head to head.

Testosterone and androgen symptoms

The same 2024 meta-analysis found a modest drop in total testosterone, and the liraglutide trial saw a lower free androgen index. But the review that informed the guideline judged published data in PCOS as very limited. Don’t expect a GLP-1 to replace treatments your doctor may suggest for acne, excess hair growth or irregular periods.

Cycles and fertility

A 2023 meta-analysis pooled 11 randomized trials with 840 women. GLP-1 medicines were linked to more regular menstrual cycles and a higher natural pregnancy rate. Total and IVF pregnancy rates didn’t differ, and the results varied a lot between studies.

How does a GLP-1 compare with metformin for PCOS?

Metformin is the long-standing PCOS medicine, and the guideline recommends it mainly for metabolic features such as insulin resistance. Head-to-head evidence is thin. In the guideline’s review, two trials comparing exenatide (an older GLP-1 medicine) with metformin found no clear differences in weight, androgen or metabolic measures, apart from slightly lower fasting glucose with metformin. The 2023 meta-analysis likewise found GLP-1 medicines alone were no better than metformin for several androgen markers. Several newer trials simply add a GLP-1 to metformin, so ask your doctor whether to keep both.

Can you get pregnant on Ozempic or Mounjaro with PCOS?

Yes, and this is the most important safety point. If your cycles were irregular before, ovulation may return as you lose weight, so pregnancy can happen sooner than you expect. Meanwhile:

• Tirzepatide (Mounjaro, Zepbound) can make birth control pills less effective for 4 weeks after starting and after each dose increase.
• Semaglutide (Ozempic, Wegovy) labels advise stopping at least 2 months before a planned pregnancy.
• If you become pregnant while using one for weight loss, the Wegovy and Zepbound labels say to stop once pregnancy is recognized.

We cover the details, including breastfeeding, in our GLP-1 birth control and pregnancy guide. If you’re hoping to conceive, the guideline lists letrozole as the preferred first-line fertility medicine. Ask your doctor how weight treatment and fertility plans fit together.

What about side effects and stopping?

Stomach side effects such as nausea are common, which is why both the labels and the PCOS guideline favor a slow start. Our dose escalation schedule guide shows the usual steps, and the nausea relief guide covers practical fixes.

The guideline also flags weight regain after stopping. Read what happens when you stop a GLP-1 before you decide how long to stay on one.

Questions to ask your doctor

Before starting

• Do I meet the criteria for a weight-management or diabetes indication, or would this be off-label?
• Which contraception should I use, especially if I take the pill?
• Should I keep taking metformin or other PCOS treatments alongside it?

During treatment

• How will we judge success: weight, waist, cycles, blood sugar, or symptoms?
• When should we recheck labs such as glucose and lipids?
• What’s the plan if I want to get pregnant?

When should you call your doctor?

• A positive pregnancy test or an unexpectedly late period
• Severe stomach pain that won’t go away, with or without vomiting
• Vomiting or diarrhea that stops you keeping fluids or your pill down
• Very heavy bleeding, or bleeding that is a big change from your usual pattern
• Swelling of the face or throat or trouble breathing (call emergency services)

The bottom line

GLP-1 medicines are a reasonable weight option for many people with PCOS, used with lifestyle support and a clear contraception plan. The evidence for periods, androgens and fertility is promising but still early. Changes in cycles can be easy to forget between appointments. GLPMate’s daily Journal and side-effect log let you jot down cycle notes next to your doses, and the doctor report brings your weight trend and dose history to your next visit.

This article is educational only and not medical advice. Talk to your doctor or gynecologist about whether a GLP-1 fits your PCOS care.

FAQ

FAQ

Is Ozempic or Mounjaro approved for PCOS?

No. Ozempic and Mounjaro are approved for type 2 diabetes, and Wegovy and Zepbound for weight management and other conditions; none lists PCOS. A doctor may prescribe one for someone with PCOS who meets the weight or diabetes criteria, and the 2023 international PCOS guideline supports considering GLP-1 medicines alongside lifestyle care for higher weight.

Does Mounjaro or Ozempic help PCOS weight loss?

In small trials in women with PCOS, GLP-1 medicines produced more weight loss than placebo or metformin alone; for example, liraglutide 3 mg led to 5.7% weight loss versus 1.4% with placebo over 32 weeks. Tirzepatide and semaglutide data in PCOS are newer and come from small open-label studies, so results in everyday life may differ.

Can a GLP-1 make you more fertile with PCOS?

It may. A 2023 meta-analysis of 11 small trials linked GLP-1 medicines to more regular cycles and a higher natural pregnancy rate, though not to higher IVF success. That means pregnancy can happen sooner than expected, so use reliable contraception and plan any pregnancy with your doctor, since these medicines should be stopped before conceiving.

Does a GLP-1 lower testosterone in PCOS?

Some trials found a modest drop in total testosterone or free androgen index, mostly alongside weight loss, but results are inconsistent and the guideline review called the evidence very limited. GLP-1 medicines aren't a replacement for treatments your doctor may recommend for acne, excess hair growth or irregular periods.